A ASSOCIAÇÃO ENTRE O USO DA TIRZEPATIDA E A INEFICÁCIA DOS ANTICONCEPCIONAIS HORMONAIS
DOI:
https://doi.org/10.63330/aurumpub.036-006Palabras clave:
Tirzepatida, Anticoncepcionais hormonais, Interação medicamentosa, GLP-1, Ineficácia contraceptivaResumen
A tirzepatida, um agonista duplo dos receptores GIP e GLP-1, tem sido amplamente utilizada no tratamento do diabetes mellitus tipo 2 e, mais recentemente, no manejo da obesidade. Apesar de sua eficácia metabólica, surgem preocupações clínicas relevantes quanto à sua interação com anticoncepcionais hormonais orais, especialmente no que diz respeito à possível redução de sua eficácia. Este artigo analisa os mecanismos farmacológicos envolvidos, as evidências clínicas disponíveis, as limitações dos estudos existentes e as implicações práticas para a saúde reprodutiva feminina.
Descargas
Referencias
1. SKELLEY, J. W.; SWEARENGIN, K.; YORK, A. L.; GLOVER, L. H.The impact of tirzepatide and glucagon-like peptide-1 receptor agonists on oral hormonal contraception. Journal of the American Pharmacists Association, 2024.Disponível em: https://pubmed.ncbi.nlm.nih.gov/37940101/.A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and the dual GLP-1/GIP receptor agonist tirzepatide. Pharmacology C Therapeutics, 2025.
2. KETTNER, J. et al.Glucagon-like peptide-1 receptor agonists and reproductive health considerations. Current Opinion in Endocrinology, Diabetes and Obesity, 2025.Disponível em: https://pubmed.ncbi.nlm.nih.gov/40906565/.
3. ELI LILLY AND COMPANY. A study of the effect of tirzepatide on the pharmacokinetics of oral contraceptives. ClinicalTrials.gov Identifier: NCT04172987.Disponível em: https://clinicaltrials.gov/study/NCT04172987.
4. MEDICINES AND MEDICAL DEVICES SAFETY AUTHORITY (MEDSAFE). Possible interaction between GLP-1 receptor agonists and oral contraceptives. Wellington, 2025.Disponível em: https://www.medsafe.govt.nz/committees/marc/reports/203-3.2.1-GLP- 1AndOralContraceptives.pdf.
5. THERAPEUTIC GOODS ADMINISTRATION (TGA).Updated contraception advice for Mounjaro (tirzepatide). Canberra, 2024.Disponível em: https://www.tga.gov.au/news/safety-updates/updated-contraception- advice-mounjaro-tirzepatide.
6. DRUGS.COM.Ethinyl estradiol and tirzepatide drug interaction report.Disponível em: https://www.drugs.com/drug-interactions/ethinyl- estradiol-with-tirzepatide-1039-0-4363-0.html.
7. REPRODUCTIVE HEALTH ACCESS PROJECT.Possible drug interaction between GLP-1 agonists and oral contraceptives.Disponível em: https://www.reproductiveaccess.org/resource/possible-drug-interaction- between-glp-1-agonist-and-oral-contraceptives/.
8. SKELLEY, J. W. et al. The impact of tirzepatide and GLP-1 receptor agonists on oral hormonal contraception. Journal of the American Pharmacists Association, 2024.Disponível em: https://www.japha.org/article/S1544- 3191(23)00370-9/pdf.
9. U.S. FOOD AND DRUG ADMINISTRATION (FDA).Mounjaro® (tirzepatide) prescribing information. Silver Spring, 2024.Disponível em: https://www.accessdata.fda.gov.
Descargas
Publicado
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
